Technology ID
TAB-3242

Regenerative Therapy for Cartilage Damage

E-Numbers
E-152-2017-0
Lead Inventor
Robey, Pamela (NIDCR)
Co-Inventors
Shirvan, Mitchell (Synerra Medical)
Gorodetsky, Rafael (Hadassah Medical Center)
Kuznetsov, Sergei (NIDCR)
Lazmi-Hailu, Astar (Hadassah Medical Center)
Applications
Therapeutics
Research Materials
Non-Medical Devices
Medical Devices
Diagnostics
Therapeutic Areas
Immunology
Geriatrics
Development Stages
Pre-Clinical (in vitro)
Lead IC
NIDCR
ICs
NIDCR
The subject technology discloses a tissue engineering method for treating cartilage damage. Stem cells from bone marrow are attached to a novel scaffold, hyaluronic acid-coated fibrin microbeads, and transferred to a live host to form cartilage. The regenerated cartilage is stable and not hypertrophic, which has been problematic in the current regenerative methods.
Commercial Applications
  • A novel scaffold, hyaluronic acid-coated fibrin microbeads.
  • Cartilage repair.
Competitive Advantages
  • Coating with hyaluronic acid makes the fibrin microbeads more stable for mature cartilage formation.
  • The new hyaline cartilage is stable and hypertrophy-resistant.

Request More Info

Licensing Contact:

Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3242] Regenerative Therapy for Cartilage Damage&body=Please send me information about technology [TAB-3242] Regenerative Therapy for Cartilage Damage.">vlado.knezevic@nih.gov</a><br>

Patents

Publications

License Status

  • Available for non-exclusive or exclusive licensing
Date Published